- Alexion Pharmaceuticals (NASDAQ:ALXN) Q2 results:
- Revenues: $1,444.6M (+20.1%); Soliris: $975.5M (-0.5%); Ultomiris: $251.1M (+363.3%); Strensiq: $184.3M (+30.4%); Kanuma: $33.6M (+28.2%).
- Net loss: ($1,068.1M); loss/share: ($4.84); non-GAAP Net Income: $702.2M (+16.1%); non-GAAP EPS: $3.11 (+17.8%).
- CF Ops: $1,339.6M (+38.3%).
- 2020 Guidance: Revenues: $5,550M - 5,600M from $5,230M - 5,330M vs. average analyst expectation of 5,390M; Soliris/Ultomiris revenues: $4,725 - 4,755M from $4,495M - 4,570M; EPS: $0.96 - 1.30 from $8.14 - 8.47; non-GAAP EPS: $10.65 - 10.95 from $10.45 - 10.75. The midpoint of analyst expectations is $10.83.
- Shares are up 2% premarket.
- Previously: Alexion Pharmaceuticals EPS beats by $0.53, beats on revenue (July 30)
Alexion beats Q2 consensus; revenue guidance raise tops estimates
Recommended For You
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ALXN | - | - |
Alexion Pharmaceuticals, Inc. |